COVID-19ACUQiGNCT05289154
Acupressure and Qigong in Chronic Fatigue Post COVID-19.
A study testing self- applied acupressure plus Qigong course plus advice literature and advice literature with naturopathy in people with COVID-19 and Post-COVID-19 Syndrome, run by Charite University, Berlin, Germany at 1 site in Germany.
Trial summary
International observational studies confirm the high incidence of post-infectious residual syndrome after infection with severe acute respiratory syndrome corona virus 2 (SARS-COV2), which can occur in 10-15% of all infected persons, regardless of the severity of the acute infection. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- COVID-19, Post-COVID-19 Syndrome
- What is being tested?
- self- applied acupressure plus Qigong course plus advice literature and advice literature with naturopathy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteGermany
- Study dates
- 14 Jun 2022to 1 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- diagnosis of chronic fatigue (after SARS-CoV2 infection)
- with at least 3 of 7 criteria at time of study inclusion: sleeping disorder, headaches, joint pain/muscle pain, anxiety/depression, memory impairment/ concentration problems, anosmia, exercise intolerance.
- acute SARS-CoV2 infection at least 12 weeks ago
- age 18-60 years
- visual analogue scale (0-100 mm) physical resilience of maximum 60 mm
- SF-36 physical function of maximum 65
- technically equipped to participate in the online intervention and willing to follow the study procedure, acupressure and Qigong to perform the exercise series at home
- written informed consent available.
Who cannot join
- fatigue already present before the SARS-CoV2 infection
- other underlying diseases leading to symptoms of chronic fatigue, such as major depression, oncological diseases, multiple sclerosis, fibromyalgia and drug abuse
- other serious underlying diseases, such as severe pulmonary, cardiac, psychiatric or infectious diseases, which could interfere with study participation or affect the results
- ongoing opioid therapy or opioid therapy in the week prior to study entry
- chronic use of cannabinoids before or during the study.
- start of psychotherapy or interruption of ongoing therapy during study participation
Show all 10Show fewer
- female participants: pregnancy or breastfeeding
- participation in another clinical intervention study during study participation
- ongoing pension procedure or planned claiming of a pension procedure due to disability
- planned inpatient rehabilitation measures during study participation due to PostCOVID-19 -
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
Charité Universitätsmedizin Campus Mitte
Berlin, 10117
Benno Brinkhaus, MD, PhD, +49 30 450 529 002, benno.brinkhaus@charite.de
Joanna Dietzel, MD, +49 30 450 529 005, joanna.dietzel@charite.de
About this study
Official title: Self- Applied Acupressure and Online Qigong for Patients Suffering From Chronic Fatigue After Corona Virus Infection 19 (COVID-19) - a Randomized Controlled Mixed-methods Study.
International observational studies confirm the high incidence of post-infectious residual syndrome after infection with severe acute respiratory syndrome corona virus 2 (SARS-COV2), which can occur in 10-15% of all infected persons, regardless of the severity of the acute infection. Post corona virus disease 19 (postCOVID-19) patients suffer mostly from symptoms such as fatigue, muscle pain, problems to focus, depression and sleep disturbances.
So far, there are no results of interventional studies for the treatment of chronic fatigue post COVID-19, but there are indicators that post COVID-19 syndrome is a chronic subclinical inflammation, similar to Chronic Fatigue Syndrome / Myalgic Encephalomyelitis CSF/ME, which also often develops from a postviral syndrome. Previously tested and effective strategies for the treatment of chronic fatigue syndrome / myalgic encephalomyelitis (CFS/ME) will be tested in the treatment of chronic fatigue postCOVID-19, in this randomized controlled trial a combination of acupressure and Qigong.
The aim of this project is to evaluate an acupressure treatment plus a Qigong exercise series specifically tailored for chronic fatigue postCOVID-19 , used daily by the patients themselves and regularly supervised, in comparison to the advice literature on the treatment of PostCOVID-19 syndrome alone.
Read the detailed description
Prospective two-arm (parallel groups) randomised controlled confirmatory intervention study with mixed methods approach in 2x 100 patients (n=200).
Intervention: self-applied acupressure and online Qigong course over 8 weeks and follow up at week 16.
Group 1: Acupressure + Qigong: Massage of the points daily for 3 minutes per point with the finger or an acupuncture pen (some points can be massaged bilaterally, therefore total approx. 20 min). In addition, twice a week an online guided Qigong course with a duration of 30-45 min. The patients should practise Qigong at least 3 times a week (including the course date). In addition, all patients will receive the guidebook literature for the treatment of complaints after SARS-CoV2 infection.
Group 2: Patients will receive advice literature on the treatment of chronic fatigue after SARS-CoV2 infection. After the end of this study the patients of this group will receive written information and video material regarding the acupressure and Qigong exercises.
- Conditions
- COVID-19, Post-COVID-19 Syndrome
- Being tested
- self- applied acupressure plus Qigong course plus advice literature, advice literature with naturopathy
- Keywords
- post COVID-19, sequelae, chronic fatigue
- Medical subject headings
- COVID-19, Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
self- applied acupressure plus Qigong course plus advice literatureOther
daily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks.
advice literature with naturopathyBehavioural
advice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls
| Study group | Role | What they receive |
|---|---|---|
| self- applied acupressure plus Qigong plus advice literature | Experimental | daily 20 min of self- applied acupressure over 8 weeks on acupuncture points Yintang, LI4, Pe6, ST36, SP6 and depending on further symptoms plus DU23/24 in hyposmia, LU7 in dyspnoea, GB34 in pain conditions, GB20 in headache OR Anmian in sleeping disorders.
The 16 sessions of 45 min Qigong course over 8 weeks will contain live online guided exercises with breathing, stretching and tapping of meridians and exercises such as the crane exercise. Receives: Other: self- applied acupressure plus Qigong course plus advice literature |
| advice literature | Active comparator | advice literature contains naturopathic remedies such as application of massage-oils, use of herbal teas, meditation techniques, breathing exercises for reconvalescence after COVID19. Receives: Behavioral: advice literature with naturopathy |
What is being measured
The primary outcome is the main question the study is designed to answer.
SF-36 Physical Function subscale
Primary study objective is to assess the changes in the mean score of the SF-36 Physical Function subscale between the two study arms assessing the degree of fatigue.
Measured: week 8
Secondary outcomes (11)
EQ5D (EuroQoL 5 domains)
disease specific QoL
Measured: week 8 and 16
SF36 PFS (Short Form 36 physical function subscale)
changes in the mean score of the SF-36 Physical Function subscale- assessing the degree of fatigue
Measured: week 16
Chalder Fatigue-Scale
Fatigue severity
Measured: week 8 and 16
VAS physical resilience (visual analogue scale)
visual analogue scale for subjective physical resilience
Measured: week 8 and 16
PHQ9 (Patient Health Questionnaire 9)
Patient Health Questionnaire assessing depression
Measured: week 8 and 16
VAS pain (visual analogue scale)
visual analogue scale for subjective pain
Measured: week 8 and 16
hand grip strength
hand grip strength
Measured: week 8 and 16
Spirometry
forced expiratory volume
Measured: week 8 and 16
autonomic dysfunction orthostasis test
heart rate and blood pressure analysis in orthostasis
Measured: week 8 and 16
d2- test
test for concentration- ability to focus
Measured: week 8 and 16
qualitative substudy
interviews regarding experience of illness and therapy
Measured: week 8 and 16
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Mar 2022
- Study start14 Jun 2022
- Primary completion1 Sep 2023 (estimated)
- Study completion1 Oct 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- More trials run by Charite University, Berlin, GermanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, randomised controlled, confirmatory intervention study with mixed methods approach
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Charite University, Berlin, Germany
- Sponsor type
- University, hospital or other
- Collaborators
- Karl and Veronica Carstens Foundation
- Responsible party
- Principal investigator, Benno Brinkhaus, Charite University, Berlin, Germany
- Investigators
- Benno Brinkhaus, PhD, Principal investigator, Charite University, Berlin, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05289154
- Sponsor's protocol ID
- ACUQiG
- Acronym
- ACUQiG
- Status last verified
- Jan 2023
- First submitted
- 18 Mar 2022
- Last updated
- 23 Jan 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, Noel A, Gunning S, Hatrick J, Hamilton S, Elvers KT, Hyams C, Bibby A, Moran E, Adamali HI, Dodd JW, Maskell NA, Barratt SL. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021 Apr;76(4):399-401. doi: 10.1136/thoraxjnl-2020-216086. Epub 2020 Dec 3.
PubMed 33273026Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
PubMed 32644129Chan JSM, Ng SM, Yuen LP, Chan CLW. Qigong exercise for chronic fatigue syndrome. Int Rev Neurobiol. 2019;147:121-153. doi: 10.1016/bs.irn.2019.08.002.
PubMed 31607352Jason L, Brown M, Evans M, Anderson V, Lerch A, Brown A, Hunnell J, Porter N. Measuring substantial reductions in functioning in patients with chronic fatigue syndrome. Disabil Rehabil. 2011;33(7):589-98. doi: 10.3109/09638288.2010.503256. Epub 2010 Jul 9.
PubMed 20617920Glasier CM, Seibert JJ, Williamson SL, Seibert RW, Corbitt SL, Rodgers AB, Lange TA. High resolution ultrasound characterization of soft tissue masses in children. Pediatr Radiol. 1987;17(3):233-7. doi: 10.1007/BF02388167.
PubMed 3295732Weyand CM, Goronzy JJ. The role of infectious agents in the etiopathogenesis of chronic rheumatic diseases. Verh Dtsch Ges Inn Med. 1990;96:319-24. doi: 10.1007/978-3-642-84317-4_58. No abstract available.
PubMed 2092449Dietzel J, Bauer T, Tissen-Diabate T, Ortiz M, Siewert J, Bellmann-Strobl J, Engelhardt U, Roll S, Grabowska W, Scheibenbogen C, Willich SN, Paul F, Brinkhaus B. Acupressure and Qigong in post-infectious fatigue with impaired physical function: a randomized clinical trial. Front Med (Lausanne). 2026 Aug 10;13:1872035. doi: 10.3389/fmed.2026.1872035. eCollection 2026.
PubMed 42638691Bauer T, Grabowska W, Ortiz M, Bellmann-Strobl J, Engelhardt U, Nogel R, Hummelsberger J, Michalsen A, Roll S, Stockigt B, Batram H, Mietzner A, Scheibenbogen C, Willich SN, Paul F, Brinkhaus B, Dietzel J. Self-medication and off-label prescribing in post COVID-19 syndrome: Baseline data of a randomized acupressure and qigong trial. Integr Med Res. 2025 Sep;14(3):101197. doi: 10.1016/j.imr.2025.101197. Epub 2025 Jul 5.
PubMed 40727709
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Self- Applied Acupressure and Online Qigong for Patients Suffering From Chronic Fatigue After Corona Virus Infection 19 (COVID-19) - a Randomized Controlled Mixed-methods Study.
- ClinicalTrials.gov ID
- NCT05289154
- Acronym / sponsor ID
- ACUQiG / ACUQiG
- Conditions
- COVID-19, Post-COVID-19 Syndrome
- Keywords
- post COVID-19, sequelae, chronic fatigue
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Charite University, Berlin, GermanyUniversity, hospital or other
- Collaborators
- Karl and Veronica Carstens Foundation
- Study start
- 14 Jun 2022 (actual)
- Primary completion
- 1 Sep 2023 (estimated)
- Study completion
- 1 Oct 2023 (estimated)
- First posted
- 21 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
International observational studies confirm the high incidence of post-infectious residual syndrome after infection with severe acute respiratory syndrome corona virus 2 (SARS-COV2), which can occur in 10-15% of all infected persons, regardless of the severity of the acute infection. Post corona virus disease 19 (postCOVID-19) patients suffer mostly from symptoms such as fatigue, muscle pain, problems to focus, depression and sleep disturbances.
So far, there are no results of interventional studies for the treatment of chronic fatigue post COVID-19, but there are indicators that post COVID-19 syndrome is a chronic subclinical inflammation, similar to Chronic Fatigue Syndrome / Myalgic Encephalomyelitis CSF/ME, which also often develops from a postviral syndrome. Previously tested and effective strategies for the treatment of chronic fatigue syndrome / myalgic encephalomyelitis (CFS/ME) will be tested in the treatment of chronic fatigue postCOVID-19, in this randomized controlled trial a combination of acupressure and Qigong.
The aim of this project is to evaluate an acupressure treatment plus a Qigong exercise series specifically tailored for chronic fatigue postCOVID-19 , used daily by the patients themselves and regularly supervised, in comparison to the advice literature on the treatment of PostCOVID-19 syndrome alone.
Detailed description
Prospective two-arm (parallel groups) randomised controlled confirmatory intervention study with mixed methods approach in 2x 100 patients (n=200).
Intervention: self-applied acupressure and online Qigong course over 8 weeks and follow up at week 16.
Group 1: Acupressure + Qigong: Massage of the points daily for 3 minutes per point with the finger or an acupuncture pen (some points can be massaged bilaterally, therefore total approx. 20 min). In addition, twice a week an online guided Qigong course with a duration of 30-45 min. The patients should practise Qigong at least 3 times a week (including the course date). In addition, all patients will receive the guidebook literature for the treatment of complaints after SARS-CoV2 infection.
Group 2: Patients will receive advice literature on the treatment of chronic fatigue after SARS-CoV2 infection. After the end of this study the patients of this group will receive written information and video material regarding the acupressure and Qigong exercises.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Prospective, randomised controlled, confirmatory intervention study with mixed methods approach
| Arm | Type | Receives |
|---|---|---|
| self- applied acupressure plus Qigong plus advice literature | Experimental | Other: self- applied acupressure plus Qigong course plus advice literaturedaily 20 min of self- applied acupressure over 8 weeks on acupuncture points Yintang, LI4, Pe6, ST36, SP6 and depending on further symptoms plus DU23/24 in hyposmia, LU7 in dyspnoea, GB34 in pain conditions, GB20 in headache OR Anmian in sleeping disorders. The 16 sessions of 45 min Qigong course over 8 weeks will contain live online guided exercises with breathing, stretching and tapping of meridians and exercises such as the crane exercise. |
| advice literature | Active comparator | Behavioral: advice literature with naturopathyadvice literature contains naturopathic remedies such as application of massage-oils, use of herbal teas, meditation techniques, breathing exercises for reconvalescence after COVID19. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- diagnosis of chronic fatigue (after SARS-CoV2 infection)
- with at least 3 of 7 criteria at time of study inclusion: sleeping disorder, headaches, joint pain/muscle pain, anxiety/depression, memory impairment/ concentration problems, anosmia, exercise intolerance.
- acute SARS-CoV2 infection at least 12 weeks ago
- age 18-60 years
- visual analogue scale (0-100 mm) physical resilience of maximum 60 mm
Key exclusion criteria (10 listed)
- fatigue already present before the SARS-CoV2 infection
- other underlying diseases leading to symptoms of chronic fatigue, such as major depression, oncological diseases, multiple sclerosis, fibromyalgia and drug abuse
- other serious underlying diseases, such as severe pulmonary, cardiac, psychiatric or infectious diseases, which could interfere with study participation or affect the results
- ongoing opioid therapy or opioid therapy in the week prior to study entry
- chronic use of cannabinoids before or during the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| self- applied acupressure plus Qigong course plus advice literaturedaily self applied acupressure over 20min plus 2 times per week online live Qigong course of each 45min- both over 8 weeks. | Other | self- applied acupressure plus Qigong plus advice literature |
| advice literature with naturopathyadvice literature with naturopathic remedies will be handed out and application will be supported with dairies and phone calls | Behavioural | advice literature |
Primary outcome
SF-36 Physical Function subscale
Time frame: week 8
Primary study objective is to assess the changes in the mean score of the SF-36 Physical Function subscale between the two study arms assessing the degree of fatigue.
11 secondary outcomes
EQ5D (EuroQoL 5 domains)
Time frame: week 8 and 16
SF36 PFS (Short Form 36 physical function subscale)
Time frame: week 16
Chalder Fatigue-Scale
Time frame: week 8 and 16
VAS physical resilience (visual analogue scale)
Time frame: week 8 and 16
PHQ9 (Patient Health Questionnaire 9)
Time frame: week 8 and 16
VAS pain (visual analogue scale)
Time frame: week 8 and 16
hand grip strength
Time frame: week 8 and 16
Spirometry
Time frame: week 8 and 16
autonomic dysfunction orthostasis test
Time frame: week 8 and 16
d2- test
Time frame: week 8 and 16
qualitative substudy
Time frame: week 8 and 16
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2023.
- Background: PubMed 33273026Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, Noel A, Gunning S, Hatrick J, Hamilton S, Elvers KT, Hyams C, Bibby A, Moran E, Adamali HI, Dodd JW, Maskell NA, Barratt SL. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021 Apr;76(4):399-401. doi: 10.1136/thoraxjnl-2020-216086. Epub 2020 Dec 3.
- Background: PubMed 32644129Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. doi: 10.1001/jama.2020.12603.
- Background: PubMed 31607352Chan JSM, Ng SM, Yuen LP, Chan CLW. Qigong exercise for chronic fatigue syndrome. Int Rev Neurobiol. 2019;147:121-153. doi: 10.1016/bs.irn.2019.08.002.
- Background: PubMed 20617920Jason L, Brown M, Evans M, Anderson V, Lerch A, Brown A, Hunnell J, Porter N. Measuring substantial reductions in functioning in patients with chronic fatigue syndrome. Disabil Rehabil. 2011;33(7):589-98. doi: 10.3109/09638288.2010.503256. Epub 2010 Jul 9.
- Background: PubMed 3295732Glasier CM, Seibert JJ, Williamson SL, Seibert RW, Corbitt SL, Rodgers AB, Lange TA. High resolution ultrasound characterization of soft tissue masses in children. Pediatr Radiol. 1987;17(3):233-7. doi: 10.1007/BF02388167.
- Background: PubMed 2092449Weyand CM, Goronzy JJ. The role of infectious agents in the etiopathogenesis of chronic rheumatic diseases. Verh Dtsch Ges Inn Med. 1990;96:319-24. doi: 10.1007/978-3-642-84317-4_58. No abstract available.
- Derived from this study: PubMed 42638691Dietzel J, Bauer T, Tissen-Diabate T, Ortiz M, Siewert J, Bellmann-Strobl J, Engelhardt U, Roll S, Grabowska W, Scheibenbogen C, Willich SN, Paul F, Brinkhaus B. Acupressure and Qigong in post-infectious fatigue with impaired physical function: a randomized clinical trial. Front Med (Lausanne). 2026 Aug 10;13:1872035. doi: 10.3389/fmed.2026.1872035. eCollection 2026.
- Derived from this study: PubMed 40727709Bauer T, Grabowska W, Ortiz M, Bellmann-Strobl J, Engelhardt U, Nogel R, Hummelsberger J, Michalsen A, Roll S, Stockigt B, Batram H, Mietzner A, Scheibenbogen C, Willich SN, Paul F, Brinkhaus B, Dietzel J. Self-medication and off-label prescribing in post COVID-19 syndrome: Baseline data of a randomized acupressure and qigong trial. Integr Med Res. 2025 Sep;14(3):101197. doi: 10.1016/j.imr.2025.101197. Epub 2025 Jul 5.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benno Brinkhaus, PhD principal investigator
Charite University, Berlin, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing self- applied acupressure plus Qigong course plus advice literature and advice literature with naturopathy in people with COVID-19 and Post-COVID-19 Syndrome, run by Charite University, Berlin, Germany at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Joanna Dietzel, MD (+49 30 450 529 002, joanna.dietzel@charite.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SF-36 Physical Function subscale (time frame: week 8). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05289154, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2023.